In many chronic inflammatory diseases, mast cells are central drivers of pathology. The paucity of mast cell-selective drugs leaves a huge unmet medical need in this area.
Targeting of mast cells via indiscriminate blocking of c-KIT signalling, while potentially efficacious, can lead to severe, dose-limiting bone marrow suppression.
Granular’s approach targets mast cells specifically & powerfully, for top-down, disease-modifying immune modulation with improved safety profile.
Company Details
- Employees
- 4
- Founded
- 2017
- Address
- Ramsgate Road, Innovation House,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Sandwich, Kent
Granular Therapeutics Ltd Questions
Granular Therapeutics Ltd's website is https://www.granulartherapeutics.com
Granular Therapeutics Ltd's LinkedIn profile is https://uk.linkedin.com/company/granular-therapeutics-ltd
Granular Therapeutics Ltd has
4 employees.
View email and phone details for 4
employees at Granular Therapeutics Ltd.
Granular Therapeutics Ltd's industry is
Biotechnology Research
Granular Therapeutics Ltd's top competitors are
Axon Integrative Health,
Graegis Pharmaceuticals,
Ottimo Pharma,
Stepping Stones Nursery - Hillingdon,
Medicxi,
Neurona Therapeutics,
Alys Pharmaceuticals,
Centessa Pharmaceuticals,
Aldena Therapeutics,
Galderma.
Granular Therapeutics Ltd's categories are Biotechnology Research
Granular Therapeutics Ltd's founding year is 2017
